American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer

Journal of Clinical Oncology

Volumn 18, Issue 6, 2000, Pages 1378-1391

  Hillner, Bruce E ^a   Ingle, James N ^a   Berenson, James R ^a   Janjan, Nora A ^a   Albain, Kathy S ^a   Lipton, Allan ^a   Yee, Gary ^a   Biermann, J Sybil ^a   Chlebowski, Rowan T ^a   Pfister, David G ^a  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PAIN; CANCER SURVIVAL; DRUG INDICATION; DRUG SAFETY; FEMALE; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 0034062815     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.6.1378     Document Type: Article

References (68)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 48:6-29, 1998
2. Fisher B, Ravdin RG, Ausman RK, et al: Surgical adjuvant chemotherapy in cancer of the breast: Results of a decade of cooperative investigation. Ann Surg 168:337-356, 1968
3. Galasko CSB: The anatomy and pathways of skeletal metastases, in Weiss L, Gilbert HA (eds): Bone Metastasis. Boston, MA, Hall Medical Publishers, 1981, pp 49-63
4. Canadian Medical Association: The Canadian task force on the periodic health examination. Can Med Assoc J 121:1193-1254, 1979
5. Cook DL, Guyatt GH, Laupacis A, et al: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 102:305S-311S, 1992 (suppl 4)
6. Sacken DL: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 95:2S-4S, 1989 (suppl 2)
7. Berenson J, Major P, Hortobagyi G: Relevant clinical end points in bisphosphonate trials. J Clin Oncol 16:3204-3205, 1998
8. Lipton A: Bisphosphonates and breast carcinoma. Cancer 80: 1668-1673, 1997
9. Body J: Bisphosphonates. Eur J Cancer 34:263-269, 1998
10. Fleisch H: Bisphosphonates: Mechanisms of action. Endocr Rev 19:80-100, 1998
11. Hortobagyi GN, Theriault RL, Porter L, et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785-1791, 1996
12. Hortobagyi GN, Theriault RL, Lipton A, et al: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16:2038-2044, 1998
13. Theriault R, Lipton A, Hortobagyi G, et al: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial - Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17:846-854, 1999
14. Thurlimann B, Morant R, Jungi WF, et al: Pamidronate for pain control in patients with malignant osteolytic bone disease: A prospective dose-effect study. Support Care Cancer 2:61-65, 1994
15. Conte PF, Latreille J, Mauriac L, et al: Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial. J Clin Oncol 14:2552-2559, 1996
16. Patterson AHG, Powles TJ, Kanis JA, et al: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65, 1993
17. van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al: Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11:491-498, 1993
18. Bloomfield D: Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 16:1218-1225, 1998
19. British Association of Surgical Oncology guidelines: The management of metastatic bone disease in the United Kingdom - The Breast Specialty Group of the British Association of Surgical Oncology. Eur J Surg Cancer 25:3-23, 1999
20. Body J, Bartl R, Burckhardt P, et al: Current use of bisphosphonates in oncology: International Bone and Cancer Study Group. J Clin Oncol 16:3890-3899, 1998
21. Scheid V, Buzdar A, Smith T, et al: Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer 58:2589-2593, 1986
22. Berruti A, Piovesan A, Torta M, et al: Biochemical evaluation of bone turnover in cancer patients with bone metastases: Relationship with radiograph appearances and disease extension. Br J Cancer 73:1581-1587, 1996
23. Vinholes J, Coleman R, Eastell R: Effects of bone metastases on bone metabolism: Implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev 22:289-331, 1996
24. Lipton A, Demers L, Curley E, et al: Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 34:2021-2026, 1998
25. Glover D, Lipton A, Keller A, et al: Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer: A dose seeking study. Cancer 74:2949-2955, 1994
26. Koeberle D, Bacchus L, Thuerlimann B, et al: Pamidronate treatment in patients with malignant osteolytic bone disease and pain: A prospective randomized double-blind trial. Support Care Cancer 7:21-27, 1999
27. Ernst DS, MacDonald RN, Paterson AH, et al: A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. J Pain Symptom Manage 7:4-11, 1992
28. Ernst DS, Brasher P, Hagen N, et al: A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 13:319-326, 1997
29. Coleman RE, Purohit OP, Vinholes JJ, et al: High dose pamidronate: Clinical and biochemical effects in metastatic bone disease. Cancer 80:1686-1690, 1997 (8 suppl)
30. Kanis JA, Powles T, Paterson AHG, et al: Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19:663-667, 1996
31. van Holten-Verzantvoort AT, Hermans J, Beex LV, et al: Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? Eur J Cancer 32A:450-454, 1996
32. Berenson JR, Lipton A: Bisphosphonates in the treatment of malignant bone disease. Ann Rev Med 50:237-248, 1999
33. Diel IJ, Solomayer EF, Costa SD, et al: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357-363, 1998
34. Powles TJ, McCloskey E, Paterson AH, et al: Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 90:704-708, 1998
35. Saarto T, Blomqvist C, Virkkunen P, et al: No reduction of bony metastases with adjuvant clodronate treatment in node-positive breast cancer patients. Proc Am Soc Clin Oncol 19:128a, 1999 (abstr 489)
36. Kanis JA, McCloskey EV, Powles T, et al: A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 79:1179-1181, 1999
37. Delmas PD, Balena R, Confravreaux E, et al: Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study. J Clin Oncol 15:955-962, 1997
38. Saarto T, Blomqvist C, Valimaki M, et al: Clodronate improves bone mineral density in postmenopausal breast cancer patients treated with adjuvant antiestrogens. Br J Cancer 75:602-605, 1997
39. Saarto T, Blomqvist C, Välimäki M, et al: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341-1347, 1997
40. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351:1451-1467, 1998
41. Ribeiro G, Swindell R: Christie Hospital adjuvant tamoxifen trial: Status at 10 years. Br J Cancer 57:601-603, 1988
42. Love RR, Mazess RB, Tormey DC, et al: Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 12:297-302, 1998
43. Chlebowski RT, Collyar DC, Somerfield MR, et al: American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene. J Clin Oncol 17:1939-1955, 1999
44. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371-1388, 1998
45. Eastell R: Treatment of postmenopausal osteoporosis. N Engl J Med 338:736-746, 1998
46. Fowble B, Hanlon A, Freedman G, et al: Postmenopausal hormone replacement therapy: Effect of diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation. J Clin Oncol 17:1680-1688, 1999
47. Chlebowski RT, McTiernan A: Elements of informed consent for hormone replacement therapy in patients with diagnosed breast cancer. J Clin Oncol 17:130-142, 1999
48. Coukell AJ, Markham A: Pamidronate: A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. Drugs Aging 12:149-168, 1998
49. Berenson JR, Lichtenstein A, Porter L, et al: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 16:593-602, 1998
50. Tyrrell CT, Bruning PF, May-Levin F, et al: Pamidronate infusions as single-agent therapy for bone metastases: A phase II trial in patients with breast cancer. Eur J Cancer 31A:1976-1980, 1995
51. Vilimovskij A, Thuerlimann JR, Berenson JR, et al: Renal safety and tolerability of 90 mg of Aredia (pamidronate) administered as an intravenous 1 hour infusion: Preliminary results. Proc Am Soc Clin Oncol 19:576a, 1999 (abstr 2223)
52. Yazawa Y, Frassica FJ, Chao EY, et al: Metastatic bone disease: A study of the surgical treatment of 166 pathologic humeral and femoral fractures. Clin Orthop 251:213-219, 1990
53. Rose CM, Kagan AR: The final report of the expert panel for the radiation oncology bone metastasis work group of the American College of Radiology. Int J Radiat Oncol Biol Phys 40:1117-1124, 1998
54. American College of Radiology (ACR) Task Force on Appropriateness Criteria: Appropriateness criteria for imaging and treatment decisions, in ACR Standard for Radiation Oncology (rev). Reston, VA, American College of Radiology, 1995, pp 217-222
55. Bates T: A review of local radiotherapy in the treatment of bone metastases and cord compression. Int J Radiat Oncol Biol Phys 23:217-221, 1992
56. Robinson RG, Preston DF, Schiefelbein M, et al: Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 274:420-424, 1995
57. Harris JR, Morrow M, Norton L: Malignant tumors of the breast, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 1997, pp 1557-1616
58. Petru E, Schmahl D: On the relevance of "second-line" cytotoxic chemotherapy in patients with metastatic breast cancer resistant to standard combinations. Wien Klin Wochenschr 98:790-797, 1986
59. Vogel CL, Azevedo S, Hilsenbeck S, et al: Survival after first recurrence of breast cancer: The Miami experience. Cancer 70:129-135, 1992
60. Koenders PG, Beex LV, Kloppenborg PW, et al: Human breast cancer: Survival from first metastasis - Breast Cancer Study Group. Breast Cancer Res Treat 21:173-180, 1992
61. Insa A, Lluch A, Prosper F, et al: Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: Analysis of 439 patients. Breast Cancer Res Treat 56:67-78, 1999
62. Buckner JC, Ingle JN, Everson LK, et al: Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer. Breast Cancer Res Treat 13:135-142, 1989
63. Clark GM, Sledge GW, Osborne CK, et al: Survival from first recurrence: Relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5:55-61, 1987
64. Hillner BE, Weeks JC, Desch CE, et al: Pamidronate in prevention of bone complications in metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol 18:72-79, 2000
65. Balducci L: Cost effectiveness of pamidronate in the treatment of breast cancer in the metastatic and in the adjuvant setting. Proc Am Soc Clin Oncol 17:415a, 1999 (abstr 1599)
66. Dranitsaris G, Hsu T: Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer 7:271-279, 1999
67. Lipton A, Berenson JR, Levy E, et al: Phase II study of the bisphosphonate zoledronate in patients with osteolytic lesions. Presented at 1999 Second Intl Conf Cancer Induced Dis, Davos, Switzerland, March 27-29, 1999
68. Body JJ, Lichinitser I, Diehl K, et al: Double-blind placebocontrolled trial of intravenous ibandronate in breast cancer metastatic to bone. Proc Am Soc Clin Oncol 19:575a, 1999 (abstr 2222)